https://www.chimeron.com/wp-content/uploads/2024/06/RECIPIENT-Innovative-Concept-Award.png
900
900
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2024/06/RECIPIENT-Innovative-Concept-Award.png
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors. As the former founding CSO of Moderna, Tony is a pioneer in RNA…
read more
Chimeron Bio Welcomes Kevin Heyeck as New CEO
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer. Kevin comes to Chimeron with a long and successful track record of executive and entrepreneurial experience in life sciences. Kevin began…
read more
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
Philadelphia, PA and College Station, TX – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and…
read more
Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine
Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM RNA delivery platform, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the…
read more
Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis
Philadelphia, PA – Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and…
read more